Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban, a potential treatment for cardiomyopathy linked to Duchenne muscular dystrophy (DMD). The decision follows positive Phase 2 trial results showing improved heart function and a favorable safety profile, addressing a critical unmet need as no approved treatments currently exist for DMD-related heart disease. The FDA has granted a rolling review, allowing Cumberland to submit sections of the application as they are completed. Next steps include FDA review of the NDA, which will include clinical trial data, natural history comparisons, and safety information.
Cumberland Pharmaceuticals' NDA filing plans for ifetroban in DMD cardiomyopathy come as a backdrop to health sector trading on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 27, 2026 03:11 WIB: out of 150 priced US health stocks, 80 rose and 70 fell. Baxter International (BAX) saw a 3.77% gain to USD 25.63 with a typical hold time of 72 days, slightly edging Bristol-Myers Squibb (BMY) which rose 3.70% to USD 63.38 and had a longer typical hold time of 91 days. AbCellera Biologics (ABCL) also rose 3.69% to USD 11.79 but had a much shorter typical hold time of 41 days and a unique 100% sell order activity on Pluang.
Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...
Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...
S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...
Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...
Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...
